公开(公告)号：MX385576B

公开(公告)日：2025-03-18

申请号：MX2019005154

申请日：2019-05-02

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： AHNAOU ABDELLAH ,  VELTER ADRIANA INGRID ,  JACOBY EDGAR ,  VAN DEN KEYBUS FRANS ALFONS MARIA ,  TRESADERN GARY JOHN ,  MACDONALD GREGOR JAMES ,  GIJSEN HENRICUS JACOBUS MARIA ,  BUIJNSTERS PETER JACOBUS JOHANNES ANTONIUS ,  DRINKENBURG WILHELMUS HELENA IGNATIUS MARIA ,  VAN ROOSBROECK YVES EMIEL MARIA

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  C07D519/00

Abstract: La presente invencion se relaciona con nuevos derivados [1,2,4]triazol[1,5- a]pirimidin-ilo como inhibidores de la fosfodiesterasa 2 (PDE2); la invencion tambien esta dirigida a composiciones farmaceuticas que comprenden los compuestos, a procesos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos y composiciones en la prevencion y el tratamiento de trastornos en los cuales esta involucrada la PDE2, tales como trastornos neurológicos y psiquiatricos.

公开(公告)号：AU2017353313C1

公开(公告)日：2022-06-09

申请号：AU2017353313

申请日：2017-10-31

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： VAN ROOSBROECK YVES EMIEL MARIA ,  VAN DEN KEYBUS FRANS ALFONS MARIA ,  VELTER ADRIANA INGRID ,  BUIJNSTERS PETER JACOBUS JOHANNES ANTONIUS ,  TRESADERN GARY JOHN ,  GIJSEN HENRICUS JACOBUS MARIA

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  C07D451/02

Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

公开(公告)号：MA52942A

公开(公告)日：2021-04-28

申请号：MA52942

申请日：2019-06-20

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： BARTOLOMÉ-NEBREDA JOSÉ MANUEL ,  BUIJNSTERS PETRUS JACOBUS JOHANNES ANTONIUS ,  LEENAERTS JOSEPH ELISABETH ,  MARTINEZ LAMENCA CAROLINA ,  OEHLRICH DANIEL ,  TRABANCO-SUÁREZ ANDRÉS AVELINO ,  TRESADERN GARY JOHN ,  VAN ROOSBROECK YVES EMIEL MARIA ,  VELTER ADRIANA INGRID

IPC: A61K31/437 ,  A61K31/44 ,  A61K31/501 ,  A61K31/5377 ,  A61P25/16 ,  A61P25/28 ,  C07D401/04 ,  C07D519/00

公开(公告)号：MA46690A

公开(公告)日：2019-09-11

申请号：MA46690

申请日：2017-10-31

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： BUIJNSTERS PETER JACOBUS JOHANNES ANTONIUS ,  GIJSEN HENRICUS JACOBUS MARIA ,  TRESADERN GARY JOHN ,  VAN DEN KEYBUS FRANS ALFONS MARIA ,  VAN ROOSBROECK YVES EMIEL MARIA ,  VELTER ADRIANA INGRID

IPC: A61P25/00 ,  A61K31/519 ,  C07D451/02 ,  C07D487/04

公开(公告)号：AU2017353313A1

公开(公告)日：2019-04-18

申请号：AU2017353313

申请日：2017-10-31

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： VAN ROOSBROECK YVES EMIEL MARIA ,  VAN DEN KEYBUS FRANS ALFONS MARIA ,  VELTER ADRIANA INGRID ,  BUIJNSTERS PETER JACOBUS JOHANNES ANTONIUS ,  TRESADERN GARY JOHN ,  GIJSEN HENRICUS JACOBUS MARIA

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  C07D451/02

Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

公开(公告)号：CA3038913A1

公开(公告)日：2018-05-11

申请号：CA3038913

申请日：2017-10-31

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： VAN ROOSBROECK YVES EMIEL MARIA ,  VAN DEN KEYBUS FRANS ALFONS MARIA ,  VELTER ADRIANA INGRID ,  BUIJNSTERS PETER JACOBUS JOHANNES ANTONIUS ,  TRESADERN GARY JOHN ,  GIJSEN HENRICUS JACOBUS MARIA

IPC: C07D487/04 ,  A61K31/519 ,  A61P25/00 ,  C07D451/02

Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.